RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
36.48
+0.22 (+0.61%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close36.26
Open36.51
Bid0.00 x 0
Ask0.00 x 0
Day's Range36.39 - 36.57
52 Week Range28.74 - 36.86
Volume917,302
Avg. Volume1,356,410
Market Cap252.06B
Beta (3Y Monthly)0.46
PE Ratio (TTM)23.76
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.07 (2.96%)
Ex-Dividend Date2019-03-07
1y Target Est40.17
Trade prices are not sourced from all markets
  • Bristol-Myers Up as Pivotal NSCLC Study Meets Primary Endpoint
    Zacks

    Bristol-Myers Up as Pivotal NSCLC Study Meets Primary Endpoint

    Bristol-Myers' (BMY) phase III study evaluating a combination regimen of Opdivo meets primary endpoint of superior overall survival in patients with advanced lung cancer in first-line setting.

  • Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab
    Zacks

    Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab

    Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.

  • U.K.’s Competition watchdog opens probe into Roche takeover of Spark Therapeutics
    MarketWatch

    U.K.’s Competition watchdog opens probe into Roche takeover of Spark Therapeutics

    The regulator said it is looking into whether the deal will result in a substantial lessening of competition, and has set Dec. 16 as its deadline to decide whether it will continue the investigation.

  • This Biotech Stock Piggybacked On Roche's Blockbuster — And Succeeded
    Investor's Business Daily

    This Biotech Stock Piggybacked On Roche's Blockbuster — And Succeeded

    Shares of Seattle Genetics entered the triple-digit club Monday after the biotech company improved upon a breast cancer treatment from Roche. Seattle stock is now in a profit-taking zone.

  • Reuters

    UPDATE 1-Roche pushes late-comer Tecentriq as new liver cancer option

    Roche's Tecentriq mixed with Avastin helped liver cancer patients live longer, a boost to the Swiss drugmaker's strategy of expanding its late-to-the-game immunotherapy into niche areas not yet dominated by rivals. Roche said on Monday it will submit overall and progression-free survival data in hepatocellular carcinoma to U.S., European and Chinese regulators in hopes of a speedy approval. The combination is "the first treatment in more than a decade to improve overall survival in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy", said Levi Garraway, Roche's new chief medical officer, without disclosing the specific survival benefit for Tecentriq and Avastin.

  • GlobeNewswire

    Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma

    OTCQX: RHHBY) today announced that the Phase III IMbrave150 study, evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib.

  • Business Wire

    Genentech’s Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular Carcinoma

    OTCQX: RHHBY), today announced that the Phase III IMbrave150 study, evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib. Safety for the combination of Tecentriq and Avastin was consistent with the known safety profiles of the individual medicines, with no new safety signals identified. “We are very pleased with the results of our study testing the combination of Tecentriq and Avastin, which marks the first treatment in more than a decade to improve overall survival in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.

  • AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review
    Zacks

    AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review

    AstraZeneca (AZN) announces acceptance of BLA seeking approval for trastuzumab deruxtecan in metastatic breast cancer by the FDA. The FDA also grants priority review.

  • Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow
    Zacks

    Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow

    FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3

  • GlobeNewswire

    Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications

    OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-related complications.

  • Business Wire

    Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications

    OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-related complications. “With the flu season rapidly approaching, we can now offer Xofluza as the first and only FDA-approved treatment option indicated specifically for those at high risk of flu complications,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. The flu has the potential to cause a variety of complications, ranging from sinus or ear infections to more serious complications such as pneumonia.

  • Roche Posts Solid Sales for First 9 Months of '19, Ups View
    Zacks

    Roche Posts Solid Sales for First 9 Months of '19, Ups View

    Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.

  • Reuters

    UPDATE 1-AstraZeneca breast cancer treatment gets FDA priority review

    AstraZeneca Plc said on Thursday that the U.S. drug regulator will give a speedy review to its experimental breast cancer treatment, which could put the British drugmaker in direct competition with bigger rival Roche Holding AG. The U.S. Food and Drug Administration (FDA) accepted AstraZeneca's application and granted the treatment, trastuzumab deruxtecan, a priority review for the treatment of HER2-positive metastatic breast cancer, the drugmaker said.

  • Pharma Giant Boosts 2019 Outlook And Confirms Looming Takeover
    Investor's Business Daily

    Pharma Giant Boosts 2019 Outlook And Confirms Looming Takeover

    Swiss drugmaker Roche boosted its full-year guidance on Wednesday and confirmed its $4.8 billion takeover of biotech Spark Therapeutics is on track for year-end. Roche stock slipped.

  • Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
    Zacks

    Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

    Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth

  • Benzinga

    The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...

  • Roche Boosts Outlook for Third Time as New Drugs Surge
    Bloomberg

    Roche Boosts Outlook for Third Time as New Drugs Surge

    (Bloomberg) -- Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.Roche Holding AG for the third time this year said sales and profit may be better than expected as its push outside cancer pays off.Sales and core earnings per share will rise by a percentage in the high-single digits this year, the Basel, Switzerland-based drugmaker said in a statement. It previously expected growth in the mid- to high-single-digits.Key InsightsGrowth drivers Ocrevus for multiple sclerosis and Hemlibra for blood clotting continued to perform last quarter, with sales of the latter gaining after U.S. regulators cleared it for use in the largest group of hemophilia patients.Roche says planned acquisition of Spark Therapeutics still expected to close by year-end despite delays.The erosion in sales for aging blockbuster cancer drugs Avastin and Herceptin wasn’t as bad as some feared in the third quarter after rivals Amgen Inc. and Allergan Plc introduced biosimilar versions of the medicines in the U.S. in July. New competition for another older drug, Rituxan, is expected to pick up in the fourth quarter.Market ReactionRoche shares rose as much as 1% in Zurich trading. The stock has climbed about 16% so far this year, roughly in line with its Basel neighbor Novartis AG and the Bloomberg European pharma index.Get MoreFor more details on the news, click here.To read the statement, click here.(Updates with share gain in market reaction section.)To contact the reporter on this story: Tim Loh in Munich at tloh16@bloomberg.netTo contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, Marthe FourcadeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Reuters

    UPDATE 2-Roche lifts 2019 sales view again as Chinese demand soars

    Swiss drugmaker Roche lifted its 2019 sales target on Wednesday for the third time this year, helped by newer medicines and as China bought more cancer drugs to treat a disease blamed for a quarter of the nation's annual deaths. Roche's full-year revenue is now seen growing at a high-single-digit percentage rate, the Basel-based company said, to what would easily top $60 billion. Over a decade, China has gone from Roche's 10th biggest market to its second-largest behind the United States, with 4.5 billion Swiss francs ($4.5 billion) in 2018 sales.

  • GlobeNewswire

    Roche reports very strong sales growth in the first nine months of 2019 – outlook raised

    Basel, 16 October 2019 Group sales increase 10%1 at constant exchange rates and 9% in Swiss francs, due to new productsPharmaceuticals Division sales up 12%, driven by high.

  • Barrons.com

    Gilead Just Named a New CFO. Is More Deal Making on the Way?

    Gilead corporate development head Andy Dickinson’s elevation to CFO means that partnerships and acquisitions will be at the center of the company’s strategy, one analyst says.

  • Amazon floods with expired food complaints: RPT
    Yahoo Finance Video

    Amazon floods with expired food complaints: RPT

    A CNBC investigation found that the website is riddled with consumer complaints about expired foods being sold by third-party merchants. Yahoo Finance’s Dan Roberts, Julia La Roche and Brian Cheung discuss on YFi AM.

  • Roche CEO Schwan Speaks as Drugmaker Boosts Outlook for Third Time
    Bloomberg

    Roche CEO Schwan Speaks as Drugmaker Boosts Outlook for Third Time

    Oct.16 -- Roche Holding AG Chief Executive Officer Severin Schwan speaks on Bloomberg Television after the Basel, Switzerland-based drugmaker, for the third time this year, said sales and profit may be better than expected as its push outside cancer pays off. He speaks on "Bloomberg Markets: European Open."

  • Rock & Roll Hall of Fame 2020 nominees announced
    Yahoo Finance Video

    Rock & Roll Hall of Fame 2020 nominees announced

    The Rock & Roll Hall of Fame nominees have been announced for 2020. Yahoo Finance's Julia La Roche, Emily McCormick, Ines Ferre and Alexis Alexis Christoforous discuss.